# Escherichia coli Nissle 1917 **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/escherichia-coli-nissle-1917 **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-18 **Evidence Score:** 8 / 10 **Category:** Other **Also Known As:** Escherichia coli Nissle 1917, EcN, E. coli Nissle, DSM 6601, Mutaflor, Nissle 1917, Probiotic E. coli strain ## Overview Escherichia coli Nissle 1917 is a non-pathogenic [probiotic](/ingredients/condition/gut-health) strain that produces [antimicrobial](/ingredients/condition/immune-support) compounds like microcins and colicins to inhibit harmful bacteria. This strain strengthens intestinal barrier function through enhanced tight junction proteins and modulates immune responses via dendritic cell activation. ## Health Benefits - Supports gut health by balancing intestinal flora, which enhances nutrient absorption and reduces digestive discomfort. - May prevent and treat gastrointestinal disorders by inhibiting the growth of harmful bacteria, reducing the risk of infections. - Enhances [immune function](/ingredients/condition/immune-support) by stimulating the production of protective antibodies, lowering the risk of infections. - Reduces [inflammation](/ingredients/condition/inflammation) by modulating cytokine production, which can alleviate symptoms of inflammatory bowel diseases. - Supports [mental health](/ingredients/condition/mood) by producing [neurotransmitter](/ingredients/condition/cognitive)s like serotonin, which can improve mood and reduce anxiety. - Enhances [skin health](/ingredients/condition/skin-health) by maintaining a balanced [gut microbiome](/ingredients/condition/gut-health), which is linked to reduced acne and eczema flare-ups. - Supports [cardiovascular health](/ingredients/condition/heart-health) by reducing cholesterol levels, as shown in studies where participants experienced a 10% reduction in LDL cholesterol. ## Mechanism of Action E. coli Nissle 1917 produces [antimicrobial](/ingredients/condition/immune-support) peptides including microcins H47 and M, along with colicins that directly inhibit pathogenic bacteria growth. The strain enhances intestinal barrier function by upregulating tight junction proteins claudin-1 and ZO-1, while stimulating dendritic cells to produce [anti-inflammatory](/ingredients/condition/inflammation) cytokine IL-10. It also competes with pathogens for iron through siderophore production and adhesion sites on intestinal epithelial cells. ## Clinical Summary Clinical trials demonstrate E. coli Nissle 1917's efficacy in maintaining ulcerative colitis remission, with studies showing comparable effectiveness to mesalamine in 327 patients over 12 months. A randomized controlled trial of 116 patients found significant reduction in IBS symptoms after 6 weeks of treatment. Meta-analyses indicate moderate evidence for preventing traveler's diarrhea and reducing antibiotic-associated diarrhea incidence. However, most studies are small-scale with heterogeneous populations, requiring larger trials for definitive therapeutic recommendations. ## Nutritional Profile - Contains live, beneficial bacteria. - Free from artificial ingredients. - Typically available in capsule or liquid form. ## Dosage & Preparation Recommended dosage is 1 to 2 capsules (around 10 billion CFU) per day. Consult a healthcare provider before use. ## Safety & Drug Interactions E. coli Nissle 1917 is generally well-tolerated with mild gastrointestinal side effects like bloating or gas in <5% of users. The strain may theoretically interact with immunosuppressive medications by enhancing immune responses, though no specific drug interactions are documented. It should be avoided in severely immunocompromised patients, those with central venous catheters, or acute pancreatitis due to rare bacteremia risk. Pregnancy and breastfeeding safety data are limited, warranting caution in these populations. ## Scientific Research Escherichia coli Nissle 1917 has been extensively studied and is one of the most researched [probiotic](/ingredients/condition/gut-health) strains for treating gastrointestinal disorders, with numerous clinical trials supporting its efficacy. ## Historical & Cultural Context Discovered during World War I, Escherichia coli Nissle 1917 has been used in Europe as a therapeutic [probiotic](/ingredients/condition/gut-health) for over a century, particularly in Germany. ## Synergistic Combinations Lactobacillus rhamnosus, Bifidobacterium bifidum, Inulin ## Frequently Asked Questions ### What is the typical dosage of E. coli Nissle 1917? The standard therapeutic dose is 2.5-25 billion CFU daily, typically taken as enteric-coated capsules to survive stomach acid. Clinical studies commonly use 5-10 billion CFU once daily for maintenance therapy. ### How long does it take for E. coli Nissle 1917 to work? Initial gut colonization occurs within 3-7 days, with measurable improvements in digestive symptoms typically appearing after 2-4 weeks of consistent use. Full therapeutic benefits for inflammatory conditions may require 6-12 weeks of supplementation. ### Can E. coli Nissle 1917 cause infections? While extremely rare, isolated cases of bacteremia have occurred in severely immunocompromised patients or those with compromised gut barriers. The strain lacks typical E. coli virulence factors and is considered safe for healthy individuals. ### Should E. coli Nissle 1917 be taken with antibiotics? It should be taken at least 2 hours apart from antibiotics to prevent bacterial killing. Some studies suggest it may help prevent antibiotic-associated diarrhea when used concurrently with appropriate timing. ### What makes E. coli Nissle 1917 different from other probiotics? Unlike typical Lactobacillus or Bifidobacterium strains, it's a Gram-negative bacterium that produces unique antimicrobial compounds like microcins. It has stronger anti-inflammatory effects and better colonization persistence in the large intestine compared to most commercial probiotics. ### Is E. coli Nissle 1917 safe for children and infants? E. coli Nissle 1917 has been used safely in pediatric populations, including infants, and is particularly beneficial for preventing antibiotic-associated diarrhea in children. However, dosing should be adjusted based on age and clinical guidance from a healthcare provider. It is generally considered safe for infants and children when administered under medical supervision. ### Does E. coli Nissle 1917 interact with common medications? E. coli Nissle 1917 typically does not interact with most medications, as it functions locally within the intestinal tract. However, certain medications like immunosuppressants or antimicrobials may affect probiotic viability or efficacy. Always consult with a healthcare provider before combining E. coli Nissle 1917 with prescription medications, especially those affecting immune function. ### What does clinical research show about E. coli Nissle 1917's effectiveness? Multiple clinical trials have demonstrated E. coli Nissle 1917's efficacy in treating and preventing inflammatory bowel conditions, reducing antibiotic-associated diarrhea, and improving overall digestive health. The evidence base is robust, with decades of research supporting its safety and efficacy in both adult and pediatric populations. Studies show comparable or superior results to some conventional probiotic strains in specific gastrointestinal conditions. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*